Importantly, a combination of CXCR4 antagonist AMD3100 or Akt inhibitor NVP-BEZ235, which targets CD133+/CD44+/CXCR4+ DU145 stem/progenitor cells plus docetaxel was also more effective at inducing the tumour growth inhibitory effect on DU145 cell xenografts in non-obese diabetic (NOD)/SCID mice and preventing the tumour re-growth after treatment cessation as compared with individual drugs [194]. This evidence concerns the gene AKT1 and neoplasm.